essais cliniques ouverts

Vous êtes patient : votre médecin est à votre disposition pour vous expliquer si votre pathologie vous rend eligible à un essai.

Qu’est ce qu’un essai clinique ?

Plus d’informations via l’INCa

Vous êtes médecin : Vous avez un patient éligible à l’un de ces essais ? Nous vous invitons à joindre le contact indiqué pour chaque essai.

Date de mise à jour: Décembre 2021


NCTTitre de l’essaiPhaseIndicationAltération génétique/marqueurCritères d’inclusionStadeLigne de traitementContactSite d’inclusion
NCT03977194Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy (ELDERLY)3Cancer du poumon non à petites cellules (NSCLC)Critèresmetastatic1marie.wislez@aphp.frCochin
NCT02313389Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma (BLOCAGE-01)3Primary Central Nervous System LymphomaCritèresnewly diagnosed1didier.bouscary@aphp.frCochin
NCT02389244A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE)2Bone SarcomaCritèrespascaline.boudou@aphp.frCochin
NCT02619630Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old) (GRAALL-2014/T)2T-cell Adult Acute Lymphoblastic LeukemiaCritères1didier.bouscary@aphp.frCochin
NCT02676349Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)2Pancreatic CarcinomaCritères Borderline resectable statusneoadjuvantromain.coriat@aphp.frCochin
NCT02734004A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA)1,2pan-tumoral (Sein, poumon, ovaire, cancer, gastro)CritèresAdvanced2jerome.alexandre@aphp.frCochin
NCT02760498Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma2Carcinome épidermoïde cutané avancéCritèreslocally advanced or metastatic1,2selim.aractingi@aphp.frCochin
NCT02866370Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium (NiCCC)2Ovarian Clear Cell Carcinoma
Endometrial Clear Cell Carcinoma
CritèresProgressive or recurrent>ou= 2bruno.borghese@aphp.frCochin
NCT02912949A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion1,2 : First in humantumeurs solides / NSCLC / cancer du pancréas NRG1 FusionNRG1 fusionCritères2marie.wislez@aphp.frCochin
NCT02924376Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy – (FIGHT-202)2CholangiocarcinomaFGFR2Critères>ou= 2romain.coriat@aphp.frCochin
NCT02959879Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma (PANACHE01)2Pancreatic Duct AdenocarcinomaCritèresResectable adenocarcinomaneoadjuvantromain.coriat@aphp.frCochin
NCT02997358Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma (LMS04)3Soft Tissue LeiomyosarcomaCritères metastatic or relapsed1jerome.alexandre@aphp.frCochin
NCT03249142Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer (INeOV)1,2ovarian cancer,fallopian tubeCritèresnewly diagnosed1jerome.alexandre@aphp.frCochin
NCT03447769Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer (Canopy-A)3Cancer du poumon non à petites cellules (NSCLC)CritèresIIA-IIIA and IIIB (atteintes résiduelles N2 seulement)2marie.wislez@aphp.frCochin
NCT03458247Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer (OPTIMABI)2Prostate cancerCritèresjerome.alexandre@aphp.frCochin
NCT03469804Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi’s Sarcoma (KAPKEY)2Kaposi SarcomaCritèresProgressive disease>ou= 2selim.aractingi@aphp.frCochin
NCT03486873Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study3pan-tumoralCritèresAdvanced or
NCT03517449Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician’s Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])3Endometrial NeoplasmsCritèresadvanced, recurrent or metastatic2jerome.alexandre@aphp.frCochin
NCT03547973Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer2Urothelial CarcinomaCritères locally advanced or  localized muscle-invasive2michael.peyromaure@aphp.frCochin
NCT03624244Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS) (BFR-ESS)2Endometrial SarcomaCritèresjerome.alexandre@aphp.frCochin
NCT03630640Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation (NIVOLEP)2Hepatocellular CarcinomaCritères2stanislas.pol@aphp.frCochin
NCT03643133Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (SARCOME13)2OsteosarcomaCritèreshigh-grade osteosarcomapost-oppascaline.bourdou@aphp.frCochin
NCT03679169Evaluation of Complete microscopicE Resection Margin (R0) and Lymph Node Involvement After Standard Pancreatosplenectomy (SPS) Versus Radical Anterograde Modular Pancreatosplenectomy (REMIND-01)Non Applicable / ChirurgieCancer du pancréasCritèresInvasive resectabledavid.fuks@aphp.frCochin
NCT03692065API-CAT STUDY for APIxaban Cancer Associated Thrombosis (API-CAT)3Cancer-associated Thrombosis – in gastro cancerCritèrestout stadetoute ligneromain.coriat@aphp.frCochin
NCT03693170Phase II, open-label, single arm, multicenter study of encorafenib, binimetinib plus cetuximab in subjects with previously untreated BRAF V600E -mutant Metastatic Colorectal Cancer 2CCRmCritèresmétastatique1romain.coriat@aphp.frCochin
NCT03745950UTOLA: UTerin OLAparib (UTOLA2Endometrial CancerMSI-High, MMR, POLE, FGFR mutations/alterationsCritèresadvanced/metastatic2jerome.alexandre@aphp.frCochin
NCT03752216NIraparib and Quality Of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. (NiQoLe)4Ovarian CancerCritèreshigh grade epithelial ovarian cancer2jerome.alexandre@aphp.frCochin
NCT03773302Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations3CholangiocarcinomaFGFR2 fusions/translocationsCritèresunresectable locally advanced or metastatic1romain.coriat@aphp.frCochin
NCT03784014Molecular Profiling of Advanced Soft-tissue Sarcomas (MULTISARC)3Soft Tissue SarcomaCritèresUnresectable locally advanced and/or metastatic STS1pascaline.bourdou@aphp.frCochin
NCT03822117Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-2072pan-tumoralFGFR genes mutations/translocationCritèresadvanced or metastatic or is surgically unresectable2jerome.alexandre@aphp.frCochin
NCT03924869Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)3Cancer du poumon non à petites cellules (NSCLC)CritèresI or IIA1marie.wislez@aphp.frCochin
NCT03940703A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)2Cancer du poumon non à petites cellules (NSCLC)MET Amplified, EGFRCritèresLocally advanced or metastatic2marie.wislez@aphp.frCochin
NCT03968419This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N)2Cancer du poumon non à petites cellules (NSCLC)CritèresStade IB-IIIA1marie.wislez@aphp.frCochin
NCT03993912Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy (IFM2017_03)3Multiple MyelomaCritères1didier.bouscary@aphp.frCochin
NCT04026412A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L)3Cancer du poumon non à petites cellules (NSCLC)CritèresLocally advanced stage IIIA, IIIB, or IIIC (T1-2 N2-3 M0, T3 N1-3 M0, or T4 N0-3 M0) 1marie.wislez@aphp.frCochin
NCT04055220Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas (REGOSTA)2Bone SarcomaCritèrespascaline.boudou@aphp.frCochin
NCT04083235A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (NAPOLI 3)A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (NAPOLI 3)3Adenocarcinoma of the PancreasCritèresmetastatic1romain.coriat@aphp.frCochin
NCT04111705Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE)2Cancer du poumon non à petites cellules (NSCLC)ALK rearrangementCritèreslocally advanced or metastatic (Stage IIIB or IV )2marie.wislez@aphp.frCochin
NCT04149574A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8)3Bladder CancerCritèresPersistent or recurrent disease>ou= 2michael.peyromaure@aphp.frCochin
NCT04163887Effect of the Laparoscopic Approach in Reducing Postoperative Severe Complications Following Hepatectomy for Colorectal Liver Metastases (METALAP)Non Applicable / ChirurgieMétastase hépatique de cancer du colonCritèresMetastatiquedavid.fuks@aphp.frCochin
NCT04163900Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer3Biliary Tract CancerCritèreslocally advanced, unresectable or metastatic1 ou 2romain.coriat@aphp.frCochin
NCT04209855A Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL)3Epithelial Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer
Critères high-grade2bruno.borghese@aphp.frCochin
NCT04233021Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (ORBITAL)2Cancer du poumon non à petites cellules (NSCLC)EGFRCritèresmetastatic (Leptomeningeal &
2, 3 or 4marie.wislez@aphp.frCochin
NCT04246489Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer2Uterine Cervical NeoplasmsCritèresadvanced unresectable and/or metastatic1,2bruno.borghese@aphp.frCochin
NCT04268121Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas (NEONEC)
2Neuroendocrine Carcinoma in gastro  Critères localizedneoadjuvantromain.coriat@aphp.frCochin
NCT04282590A Study to Investigate the Safety and Efficacy of TRK-750 for the Treatment of Patients With CIPN (Chopin Study)2Chemotherapy-induced Peripheral Neuropathy – in Gastro cancerCritères2romain.coriat@aphp.frCochin
NCT04307277Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Grade 1 or 2 Soft Tissue Sarcoma (CHIC-STS01)3Soft tissue sarcomaCritèresResectable and localized diseasePéri-oppascaline.bourdou@aphp.frCochin
NCT04325425Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary (FOLFIRINEC)2Neuroendocrine Carcinoma in gastro  CritèresGrade 3 or high grade MiNEN1romain.coriat@aphp.frCochin
NCT04463771Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.2Endometrial CancerCritèresAdvanced or Metastatic2jerome.alexandre@aphp.frCochin
NCT04475939Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo and Pembrolizumab as Maintenance Therapy (ZEAL-1L)3Cancer du poumon non à petites cellules (NSCLC)Without known alterationCritèresAdvanced (Stage IIIB not amenable to definitive chemoradiotherapy) or metastatic (Stage IV) 2marie.wislez@aphp.frCochin
NCT04526782ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF)2Cancer du poumon non à petites cellules (NSCLC)BRAFCritèresStage IV2marie.wislez@aphp.frCochin
NCT04547504PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % (PERSEE)3Cancer du poumon non à petites cellules (NSCLC)PDL1 (expression >50%)CritèresStage IV or . Unresectable and non-eligible to radiotherapy stage III 1marie.wislez@aphp.frCochin
NCT04624204Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)3Cancer du poumon à petites cellules (SCLC)Critèreslocally (Limited-Stage SCLC (Stage I-III)1marie.wislez@aphp.frCochin
NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent 3Endometrial NeoplasmsCritèresnewly diagnosed1jerome.alexandre@aphp.frCochin
NCT04641247A randomized,  double-blindphase 3 comparison of platinum-based therapy with TSR-042 and Niraparib versus standard of care platinum-based therapy as first-line treatment of stage 3 or 4 non mucinous epithelial ovarian cancer (TESARO FIRST)3Epithelial Ovarian CancerCritèresjerome.alexandre@aphp.frCochin
NCT04757337Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients (GERICO14)3Soft tissue sarcomaCritèrespascaline.boudou@aphp.frCochin
NCT04791735Value of the Laparoscopic Approach in the Surgical Management of Resectable Hepatocellular Carcinoma (LapCHC)Non Applicable / ChirurgieHepatocellular CarcinomaCritèresdavid.fuks@aphp.frCochin
NCT04621188Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)2Non-Small Cell Lung CancerCritèresmarie.wislez@aphp.frCochin 
NCT04623775Study of Relatlimab plus Nivolumab in combination with chemotherapy vs.Nivolumab in combination with chemotherapy 2Non-Small Cell Lung CancerCritèresStage IV or recurrent 1marie.wislez@aphp.frCochin 
NCT04746924A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer3lung cancerCritèresmarie.wislez@aphp.frCochin 
NCT04940325Datopotamab (DS-1062a) in advanced and/or  unresectable non-small lung cancer 2Non-Small Cell Lung CancerCritèresAvanced and/or unresectable 2 et plus marie.wislez@aphp.frCochin 
NCT04956692Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)3lung cancerCritèresmarie.wislez@aphp.frCochin 
NCT03353831Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in
early relapse Ovarian cancer
3Ovarian CancerCritè, nicolas.delanoy@aphp.frCochin/HEGP
NCT03598270Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA)3Ovarian CarcinomaCritèreshigh- grade serous or endometrioid ovarian, primary peritoneal or tubal carcinoma1,2,, anne-sophie.bats@aphp.frCochin/HEGP
NCT03799835Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients (ALBAN)3Bladder CancerCritèresT1 tumor and/or
High grade (WHO 2004) and/or
Grade 3 (WHO1973) and/or
Carcinoma in situ
NCT03924895Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer3Bladder cancerCritèresPé,
NCT04194944A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)3Cancer du poumon non à petites cellules (NSCLC)Ret-fusionCritèresAdvanced or metastatic : Stage IIIB-IIIC or Stage / francoise.lepimpec-barthes@aphp.frCochin/HEGP
NCT02416388Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR (BIG-1)2,3Acute Myeloid Leukemia (AML)Critèresnewly diagnosed de novo or secondary type, felipe.suarez@aphp.frCochin/Necker
NCT02215265 reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer (PATHOS)3Carcinome épidermoïde de l’oropharynx  HPV-induitCritèresoperable, locally advancedAdjuvanthaitham.mirghani@aphp.frHEGP
NCT02260505 A randomized, multicentre, Phase III trial evaluating the interest of imatinib treatment maintenance or interruption after 3 years of adjuvant treatment in patients with Gastrointestinal Stromal Tumours (GIST) 3GISTKIT positivityCritèresAdjuvantAdjuvantJulien Taieb : jtaieb75@gmail.comHEGP
NCT02355379Randomised phase III trial evaluating adjuvant chemotherapy after the stage III colon adenocarcinoma resection for patient of 70 year old or more3Cancer du colonCritèresAdjuvant/Stage IIIAdjuvantJulien Taieb : jtaieb75@gmail.comHEGP
NCT02502370Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma 3INTESTIN GRELECritèresAdjuvantAdjuvantJulien Taieb : jtaieb75@gmail.comHEGP
NCT02566772Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer1,2Cancer de la prostateCritères1 ou 4stephane.oudard@aphp.frHEGP
NCT02715284Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors (GARNET)1pan-tumoralCritères recurrent or advanced solid tumor2jacques.medioni@aphp.frHEGP
NCT02945033Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk (ASPIK French)3Cancer du colonPI3KCritèresAdjuvant/Stage II-IIIAdjuvantJulien Taieb : jtaieb75@gmail.comHEGP
NCT02967289A Phase III, Randomised, international trial comparing mFOLFIRINOX triplet chemotherapy to mFOLFOX for high- risk stage III colon cancer in adjuvant setting 
3Cancer du colonCritèresAdjuvant/Stage IIIAdjuvantJulien Taieb : jtaieb75@gmail.comHEGP
NCT03138512A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney (CheckMate 914)3Renal Cell CarcinomaCritères>1stephane.oudard@aphp.frHEGP
NCT03157128Phase 1/2 Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)1,2 : First in humanpan-tumoralRet-fusionCritèreslocally advanced or metastatic1,2jacques.medioni@aphp.frHEGP
NCT03164655A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only colorectal metastases considered still non resectable after at least two months of systemic induction chemotherapy: SULTAN (improving SUrgery of Liver metastases: a Trial of the Arterial chemotherapy Network) 2Cancer du colonCritèresMétastases hépatiques2Julien Taieb : jtaieb75@gmail.comHEGP
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors1,2pan-tumoralCritèresinoperable, locally advanced, metastatic, or recurrent1 ou 2jacques.medioni@aphp.frHEGP
NCT03178552A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST2,3Non-Small Cell Lung CancerCritèresUnresectable stage IIIB or IV >1francoise.lepimpec-barthes@aphp.frHEGP
NCT03353832Atezolizumab in combination with Bevacizumab and Chemotherapy
versus Bevacizumab and Chemotherapy
in recurrent ovarian cancer (AGO-OVAR 2.29)
3cancer épithélial de l’ovaire, des trompes de Fallope ou du péritoineCritèresMetastatic       >1        <4nicolas.delanoy@aphp.frHEGP
NCT03362177Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer3Chemotherapy-induced ThrombocytopeniaCritèresAllJulien Taieb : jtaieb75@gmail.comHEGP
NCT03364530Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma2Intra-hepatic CholangiocarcinomeCritèresNon résecable-Non Métastatique2Julien Taieb : jtaieb75@gmail.comHEGP
NCT03390504A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations3Carcinome urothélialFGFRCritèresadvanced or metastatic2,3jacques.medioni@aphp.frHEGP
NCT03395197Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2)3Metastatic Castration-Resistant Prostate Cancer (mCRPC)CritèresMetastatic2stephane.oudard@aphp.frHEGP
NCT03469674PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer3Endometrial Cancer CritèresStage I, Stage IIcatherine.durdux@aphp.frHEGP
NCT03473743Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer1,2Carcinome urothélialCritèresmetastatic or locally advanced1,2jacques.medioni@aphp.frHEGP
NCT03556839Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix (BEATcc)3Carcinoma of the CervixCritèresmetastatic (stage IVB), persistent, or recurrent1anne-sophie.bats@aphp.frHEGP
NCT03579394Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer (CHRONO)3Ovarian CancerCritèresStage III, IV1anne-sophie.bats@aphp.frHEGP
NCT03602859A Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)3Ovarian CancerCritèresStage III, IV1nicolas.delanoy@aphp.frHEGP
NCT03656536A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma3Cholangiocarcinome Réarrangement FGFR2 CritèresLA-Métastatique1Julien Taieb : jtaieb75@gmail.comHEGP
NCT03659136The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread2breast cancerER + or/and PgR + & HER2 –CritèresLocally advanced or metastatic1,2jacques.medioni@aphp.frHEGP
NCT03701334A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE)3Breast cancerER + or/and PgR + & HER2 –Critèresearly invasive1jacques.medioni@aphp.frHEGP
NCT03719924Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma3Carcinome Epidermoïde de l’oesophageCritèresMétastatique2Julien Taieb : jtaieb75@gmail.comHEGP
NCT03722108Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas 2Adénocaecinome oeso-gastrique CritèresMétastatique2Julien Taieb : jtaieb75@gmail.comHEGP
NCT03737643Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients.3Advanced Ovarian CancerCritèresadvanced (Stage III-IV)1anne-sophie.bats@aphp.frHEGP
NCT03748134Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma3Carcinome Epidermoïde de l’oesophageCritèresLA-Métastatique1Julien Taieb : jtaieb75@gmail.comHEGP
NCT03765918Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)3Cancer ORLCritèresAdvancedpré/post-opaudrey.simonaggio@aphp.frHEGP
NCT03783442A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma3Esophageal Squamous Cell Carcinoma (ESCC)CritèresUnresectable, locally advanced recurrent or metastatic1Julien Taieb : jtaieb75@gmail.comHEGP
NCT03785925A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer (PIVOT-10)2Carcinome urothélialCritèresmetastatic or locally advanced1jacques.medioni@aphp.frHEGP
NCT03809988PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (PALMIRA)2breast cancerER + or/and PgR + & HER2 –CritèresAdvanced1,2jacques.medioni@aphp.frHEGP
NCT03829462A randomized phase III trial assessing a regorafenib-irinotecan combination (REGIRI) versus regorafenib alone in metastatic colorectal cancer patients after failure of standard therapies, according to the A/A genotype of Cyclin D1 3Cancer du colon génotype A/A (rs9344) de la cycline D1 

CritèresMétastatique≥2Julien Taieb : jtaieb75@gmail.comHEGP
NCT03833154Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer Patients (PACIFIC-4)3Carcinoma, Non-Small-Cell LungCritèresStage I to II NSCLCfrancoise.lepimpec-barthes@aphp.frHEGP
NCT03842982Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)3Ovarian CancerCritèresStage III2anne-sophie.bats@aphp.frHEGP
NCT03899155Pan Tumor Nivolumab Rollover Study2pan-tumoralCritèresjacques.medioni@aphp.frHEGP
NCT03937219Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313)3Renal Cell CarcinomaCritèresadvanced or metastatic (AJCC Stage IV)1stephane.oudard@aphp.frHEGP
NCT03959293Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma2Adénocaecinome oeso-gastrique CritèresMétastatique2Julien Taieb : jtaieb75@gmail.comHEGP
NCT03976375Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)3Cancer du poumon non à petites cellules (NSCLC)Critèresmetastatic (Stage IV: M1a, M1b, M1c)2jacques.medioni@aphp.frHEGP
NCT04006262Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma2Adénocaecinome oeso-gastrique dMMR et/ou MSICritèresPéri-opPéri-opJulien Taieb : jtaieb75@gmail.comHEGP
NCT04034459FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC2Cancer du colonBRAF muté (V600E).   RAS wtCritèresMétastatique1Julien Taieb : jtaieb75@gmail.comHEGP
NCT04100018A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer (CheckMate 7DX)3Prostate CancerCritèresmetastatic> ou = 2stephane.oudard@aphp.frHEGP
NCT04109066Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL)3Breast cancerER + and HER2 –CritèresLocalized invasive1anne-sophie.bats@aphp.frHEGP
NCT04120701Circulating tumor dna based decision for adjuvant treatment in colon cancer stage II

3Cancer du colonCritèresAdjuvant/Stage II-AdjuvantJulien Taieb : jtaieb75@gmail.comHEGP
NCT04154956SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients (CARMEN-LC03)3Cancer du poumon non à petites cellules (NSCLC)CEACAM5 positiveCritèresmetastatic2jacques.medioni@aphp.frHEGP
NCT04197986Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations3Carcinome urothélialFGFR3Critèresinvasiveadjuvantjacques.medioni@aphp.frHEGP
NCT04209114A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer3Cancer de la vessieCritèresmuscle-invasivepré/post-opjacques.medioni@aphp.frHEGP
NCT04348045Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients (D19-02)2Adénocarcinome du PancreasBRCA / KRASSCritèresMétastatique1Julien Taieb : jtaieb75@gmail.comHEGP
NCT04398524A Phase II Study of cemiplimab , an anti PD 1
monoclonal antibody, and ISA101b vaccine in patients with recurrent/metastatic HPV16 positive Oropharyngeal Cancer who have experienced disease progression with prior anti PD 1 therapy
2Cancer ororpharyngé HPV16CritèresRécidivant / Métastatique>1haitham.mirghani@aphp.frHEGP
NCT04446117Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)3Metastatic Prostate Cancer
Prostate Adenocarcinoma
NCT04450836Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer (SOREGATT)2Cancer du colonCritèresMétastatique≥2Julien Taieb : jtaieb75@gmail.comHEGP
NCT04456699A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003) 
3Cancer du colonCritèresMétastatique1Julien Taieb : jtaieb75@gmail.comHEGP
NCT04478266Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer2,3Breast CancerER + and HER2 –Critèresloco-regional recurrent or metastatic1anne-sophie.bats@aphp.frHEGP
NCT04527991A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPICS-04)3Cancer urothelialCritèresmetatstatic or locally advanced unresectable3, 4, 5constance.thibault@aphp.frHEGP
NCT04543617A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy3Carcinome Epidermoïde de l’oesophageCritèresLA1Julien Taieb : jtaieb75@gmail.comHEGP
NCT04586244« An Open-Label, Randomized, Phase 2, Umbrella Study of Various
Neoadjuvant Therapies for Participants With Muscle-Invasive Urothelial
Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse
Cisplatin Therapy and Undergoing Radical Cystectomy (Optimus) »
2Cancer urothelialCritèresCisplatin-ineligible1constance.thibault@aphp.frHEGP
NCT04592913A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC) (Matterhorn)3Adénocarcinome oeso-gastrique CritèresPéri-opPéri-opAziz ZAANAN aziz.zaanan@aphp.frHEGP
NCT04622319A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)3breast cancerHER2 +CritèresStade III1jacques.medioni@aphp.frHEGP
NCT04640623A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (SunRISe-1)2high-risk Non-Muscle Invasive Bladder Cancer Critèresmarc-olivier.timsit@aphp.frHEGP
NCT04658862A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2)3Muscle-Invasive Urothelial Carcinoma (MIBC) Critèresmarc-olivier.timsit@aphp.frHEGP
NCT04704934A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects With HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)3Adénocaecinome oeso-gastriqueHER2 positifCritèresLA-Métastatique2Aziz ZAANAN aziz.zaanan@aphp.frHEGP
NCT04720157An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition)3Cancer de la prostateCritères1stephane.oudard@aphp.frHEGP
NCT04732494A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Plus Anti-TIGIT Monoclonal Antibody BGB-A1217 Versus Tislelizumab Plus Placebo as Second-Line Treatment in Patients With PD-L1 vCPS ≥ 10% Unresectable, Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (BGB-A317-A1217-203)2Carcinome Epidermoïde de l’oesophageCritèresLA-Métastatique2Aziz ZAANAN aziz.zaanan@aphp.frHEGP
NCT04737187Phase III study of trifluridine/tipiracil in combination with bevacizumab vs trifluridine/tipiracil single agent in patients with refractory metastatic colorectal cancer 3Cancer du colonCritèresMétastatique2,3Julien Taieb : jtaieb75@gmail.comHEGP
NCT02820857Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer2tumeur neuroendocrineCritèresLA-Métastatique2Julien Taieb : et romain.coriat@aphp.frHEGP/Cochin
NCT02885753Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver (OSCAR)3Cancer du colonCritèresMétastases hépatiques1Julien Taieb : et romain.coriat@aphp.frHEGP/Cochin
NCT03006432Phase III randomised trial to evaluate FOLFOX with or without docetaxel (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric carcinoma3Adénocaecinome oeso-gastrique HER-2 négativeCritèresMétastatique1Julien Taieb : et romain.coriat@aphp.frHEGP/Cochin
NCT03186326Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (SAMCO)2Cancer du colonMSICritèresMétastatique2Julien Taieb : et romain.coriat@aphp.frHEGP/Cochin
NCT03351296Randomized phase 2 trial of two chemotherapy regimens plus or minus bevacizumab in patients with well differentiated pancreatic neuroendocrine tumors 2tumeur neuroendocrine du pancréasCritèresLA-Métastatique1Julien Taieb : et romain.coriat@aphp.frHEGP/Cochin
NCT03549715NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma (NEMIO)1,2Carcinome urothélial infiltrant de la vessieCritè / michael.peyromaure@aphp.frHEGP/Cochin
NCT03584711A Phase II Study Evaluating FOLFOX + Panitumumab According to a « Stop and go » Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation2Cancer du colonRAS wt; BRAF wtCritèresMétastatique1Julien Taieb : et romain.coriat@aphp.frHEGP/Cochin
NCT03591731A GCO trial exploring the efficacy and safety of Nivolumab monotherapy or Nivolumab plus Ipilimumab in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) 2tumeur neuroendocrineCritèresLA-Métastatique2,3Julien Taieb : / / francoise.lepimpec-barthes@aphp.frHEGP/Cochin
NCT03693677First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI2Adénocarcinome du PancreasCritèresMétastatique1Julien Taieb : et romain.coriat@aphp.frHEGP/Cochin
NCT03760822Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients2Adénocaecinome oeso-gastrique CritèresMétastatique2Julien Taieb : et romain.coriat@aphp.frHEGP/Cochin
NCT03875781Non inferiority multicenter phase III randomized trial comparing preoperative chemotherapy only to chemotherapy followed by chemoradiotherapy for locally advanced resectable rectal cancer 2Cancer du RectumCritèresPré-opératoirePré-opJulien Taieb : et romain.coriat@aphp.frHEGP/Cochin
NCT04167007FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX3Adénocarcinome du PancreasCritèresMétastatique1Julien Taieb : et romain.coriat@aphp.frHEGP/Cochin
NCT04392479TWICE-IRI: Optimization of second-line therapy with aflibercept, irinotecan (day 1 or day 1,3), 5-Fluorouracile and folinic acid in patients with metastatic colorectal cancer. A randomized Phase III study. 
3Cancer du colonCritèresMétastatique2Julien Taieb : et romain.coriat@aphp.frHEGP/Cochin
NCT02283775A Phase 1b Study of SAR650984 (Isatuximab) in Combination With Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma1myelomaCritèreslaurent.frenzel@aphp.frNecker
NCT03249870A Phase 2 Study of Inotuzumab Ozogamicin (INO) Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor Acute Lymphoblastic Leukemia2LeukemiaCritèresfelipe.suarez@aphp.frNecker
NCT03366272Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients (NIVEAU)3lymphomaCritèresdavid.sibon@aphp.frNecker
NCT03503409IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome2MyélodysplasieCritèresfelipe.suarez@aphp.frNecker
NCT03836014A Multi-center Phase III Randomized Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma3Multiple MyelomaCritèreslaurent.frenzel@aphp.frNecker
NCT03839771A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML)3LeukemiaCritèresambroise.marcais@aphp.frNecker
NCT03871829A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and Dexamethasone (DKd) Compared With Carfilzomib and Dexamethasone (Kd) in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab to Evaluate Daratumumab2Multiple MyelomaCritèreslaurent.frenzel@aphp.frNecker
NCT04002297Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma3lymphomaCritèresolivier.hermine@aphp.frNecker
NCT04027309A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML)3LeukemiaCritèresambroise.marcais@aphp.frNecker
NCT04531046Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation2lymphomaCritèresmorgane.cheminant@aphp.frNecker
NCT04554914An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects With Epstein-Barr Virus-associated Diseases2EBV assaociated diseasesCritèresfelipe.suarez@aphp.frNecker
NCT04688983An Open Label, 3-arm, Randomised Phase II Study to Compare the Safety and Efficacy of Ponatinib in Combination With Either Chemotherapy or Blinatumomab With Imatinib Plus Chemotherapy as Front-line Therapy for Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL)2leukemiaCritèresambroise.marcais@aphp.frNecker
NCT04751877Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years)3Multiple MyelomaCritèreslaurent.frenzel@aphp.frNecker
NCT04984837Study of Lacutamab in Peripheral T-cell Lymphoma2lymphomaCritèresmorgane.cheminant@aphp.frNecker
NTC04703192Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)2lymphomaCritèresolivier.hermine@aphp.frNecker